ACOG's 2026-27 respiratory vaccine guidance, estradiol patch supply update, and more

Thank you for visiting the Contemporary OB/GYN website. Take a look at some of our top stories from the past week (Monday, August 31, to Friday, September 4, 2026) and click on each link to read and watch anything you may have missed.

FDA working with manufacturers to increase access to estradiol transdermal patches

The FDA stated it is working with all 6 estradiol transdermal patch manufacturers to increase supply, following multiple reports of patients struggling to access their usual amount amid increased demand tied to menopause label changes made in November 2025.

Click here for the full article.

GLP-1 receptor agonists in early pregnancy: What ob-gyns should know

A meta-analysis of more than 47,000 pregnancies exposed to GLP-1 receptor agonists shortly before or during early pregnancy found no increased risk of major maternal complications, though Elizabeth Jasper, PhD, assistant professor at Vanderbilt University Medical Center, cautions the underlying evidence remains heterogeneous and largely observational.

Click here to read the full Q&A with Elizabeth Jasper, PhD.

ACOG's 2026-27 respiratory virus immunization recommendations in pregnancy, postpartum

ACOG has released updated guidance strongly recommending COVID-19, RSV, and influenza vaccination for all women who are pregnant, postpartum, or contemplating pregnancy ahead of the 2026-27 respiratory virus season, including an extension of the RSV vaccine eligibility window through March 1.

Click here for the full article.

From PCOS to PMOS: A welcome and more inclusive name

Heather Appelbaum, MD, FACOG, Melanie Cree, MD, PhD, and Michelle Maresca, MD, react to the global renaming of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) in the first of a 5-episode special report series examining what the shift means for diagnosis, management, and patient care.

Click here to watch.

David Shalowitz, MD, on strengthened evidence behind salpingectomy for ovarian cancer prevention

Robust new effectiveness and safety data in average-risk patients, including a British Columbia cohort showing a 78% relative reduction in lifetime ovarian cancer risk, prompted ACOG's strengthened recommendation for routine bilateral salpingectomy during obstetric and gynecologic surgeries, according to David Shalowitz, MD, MSHP, Director, Cancer Care Delivery, Carewell Health.

Click here to watch the full discussion with David Shalowitz, MD, MSHP.